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SET is a multifunctional protein, but when present in the cytoplasm, acts as a powerful inhibitor of
phosphatase 2A. We previously observed that in CA1 of Down syndrome (DS) patients, the level of SET is
increased, and SET is translocated to the cytoplasm and associated with the hyperphosphorylation of tau
at ser202/thr205. The presence of SET in the cytoplasm in DS brains may play a role in the progression of
the disease. Here, we show that in CA1 of 3-month-old Ts65Dn mice modeling DS, SET level is increased,
and SET is translocated to the cytoplasm and associated with tau hyperphosphorylations at ser202/
thr205 and with amyloid precursor protein caspase cleaved as observed in Alzheimer disease brains. Tau
hyperphosphorylation at ser356 and activation of other phosphatase 2A targets such as the mammalian
target of rapamycin and adenosine monophosphate protein kinases were also observed, suggesting
deleterious mechanisms. We propose Ts65Dn mice as a model for therapeutic approaches focused on SET
overexpression and its cytoplasmic translocation to slow down disease progression.
 2016 Elsevier Inc. All rights reserved.1. Introduction
Down Syndrome (DS) is the most common form of intellectual
disability and results in a very large genetic risk for Alzheimer dis-
ease (AD). Although improved care of individuals with DS has
signiﬁcantly increased their life expectancy, it has led to a notable
and concomitant increase in the number of adults with DS aged
35e55 years with AD type dementia (Coppus et al., 2012; Hartley
et al., 2015; Strydom et al., 2013). Remarkably, almost 100% of
adultswithDS present deposition ofmicroscopic amyloid plaques in
their brains from early adult life. Treatments to slow down, stop, or
prevent the risk of DS patients to shift to AD need to be developed.
In addition to amyloid deposits, tau hyperphosphorylation and
neuroﬁbrillary tangles (NFTs) are present in the brain of elderly DS
individuals (Hartley et al., 2015). Tau hyperphosphorylation results
from an increase of kinase and/or a decrease of phosphatase
activity, which are both present in DS. Indeed, Dyrk1A kinase that
phosphorylates tau at several sites is encoded by a gene mapping to
human chromosome 21, and thus is overexpressed and accumulates
in NFTs in DS patients (Kimura et al., 2007; Liu et al., 2008; Ryoocartes, Sorbonne Paris Cité,
892 41; fax: 33 1 458 072 93.
. Allinquant).
ll rights reserved.et al., 2007). In addition, a speciﬁc decrease of phosphatase 2A
(PP2A), the major phosphatase involved in tau dephosphorylation,
is present in DS brains, whereas phosphatases 1, 2B, and 5 are un-
modiﬁed (Liang et al., 2008). Decrease of PP2A activity may be
associatedwith the presence of the PP2A inhibitor 2, also called SET,
in the neuronal cytoplasm. SET is a multifunctional protein that
inhibits the acetylation of histones, acts as a transcription factor,
stimulates cdk5 activity, and inhibits PP2A (Compagnone et al.,
2000; Li et al., 1996; Qu et al., 2002; Seo et al., 2001). In CA1 of
AD and DS patients (45e58 year old), we found that SET is increased
and translocated to the cytoplasm (Facchinetti et al., 2014). When
located in the neuronal cytoplasm, SET binds to PP2A, inhibiting its
activity and leading to an increase in tau phosphorylation. (Arnaud
et al., 2011; Bolognin et al., 2012; Chasseigneaux et al., 2014;
Chohan et al., 2006; Wang et al., 2010). In AD brains, SET trans-
locationwas correlated to the increase of amyloid precursor protein
caspase cleaved in its C-terminal part (APPcc). In addition, the
overexpression of APPcc in the CA1 of wild-type mice leads to the
translocation of endogenous SET and increase of tau phosphoryla-
tion at ser202/thr205 (Facchinetti et al., 2014). Thus SET appears as
an actor of the progression of the disease.
Here, we analyzed SET level and translocation in CA1 of Ts65Dn
mice, the best-characterized andmost widely used mouse model of
DS, trisomic for a segment of chromosome 16 extending between
Fig. 1. Increase of SET, its translocation to the cytoplasm, tau hyperphosphorylations (P-tau) at ser202/thr205/ser356, and activation ofmTOR/AMPK signaling pathways are present in
CA1 of Ts65Dnmice. (AeC) SETand P-tau immunolabelings of brain slices from 6 Ts65Dn and 5 euploid littermates were analyzed by confocal microscopy and quantiﬁedwith Volocity
software. Fluorescence intensities expressed in arbitrary unit (AU) of SET both in nuclei and neurites (A), translocated SET in neurites (B), and P-tau at ser202/thr205 both in nuclei and
neurites (C) are shown. (D) Confocal representative images of immunolabelings of SET (Alexa 488) and P-tau (cy3) are shown. P-tau is immunodetected using AT8 antibody. Nuclei are
labeledwith TOPRO-3 and shown in blue. The arrowand arrowhead show 2 examples of SETand P-tau colocalization in neurites. Scale bar: 10 mm. (E) RepresentativeWestern blots for
SET, P-tau at ser202/thr205, ser356, P-mTOR, P-P70S6K, and P-AMPK in hippocampal extracts of Euploid (E) and Ts65Dn (Ts) mice (30 mg of proteins loaded). Quantiﬁcation of SET is
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orthologues of human chromosome 21 genes (Sturgeon and
Gardiner, 2011). This murine model recapitulates several funda-
mental features of DS, including cognitive deﬁcits and alterations in
brain morphology and function (Reeves et al., 1995). We show here
that SET is overexpressed and translocated to the cytoplasm and
that tau is hyperphosphorylated at ser202/thr205 in CA1 of Ts65Dn
mice modeling DS, as in the brain of DS individuals. These events
are correlated with an increase of APPcc. Additional Tau hyper-
phosphorylation at ser356 and activation of mammalian target of
rapamycin (mTOR) and adenosine monophosphate protein kinase
(AMPK) signaling pathways are observed in hippocampi of Ts65Dn,
suggesting deleterious mechanisms.
2. Material and methods
2.1. Animals and ethics
Male mice were produced from breeders of the Jackson Labo-
ratories (B6EiC3Sn.BLi males with B6EiC3Sn.BLiA-Ts(1716)65Dn/
DnJ females). All experiments were conducted in accordance with
the ethical standards of French and European regulations (Euro-
pean Communities Council Directive of 24 November 1986). The
supervisor of in vivo studies (Marie-Claude Potier) received
ofﬁcial authorization from the French Ministry of Agriculture to
carry out research and experiments on animals (authorization no.
A-75-2138). Mice were genotyped as previously described (Duchon
et al., 2011).
2.2. Antibodies
Primary antibody for Amyloid Precursor Protein caspase cleaved
(Millipore, AB 5942, Saint-Quentin en Yvelines, France) was diluted
to 1/200. SET primary antibody (Santa-Cruz H-120, Heidelberg,
Germany) was diluted to 1/100 for immunohistochemistry. Its
speciﬁcity was checked previously (Facchinetti et al., 2014). Tau
phosphorylated at ser202/thr205 (AT8 antibody Innogenetics,
BR-03, Courtaboeuf, France) was used to 1/200 for immunohisto-
chemistry as previously used (Facchinetti et al., 2014).
For Western blotting, SET and AT8 antibodies were diluted to
1/500, tau phosphorylated at ser356 (ab 75603, Abcam, Cambridge,
UK) was diluted to 1/1000; anti-Tau-5 for total Tau (mAb 577801,
Calbiochem, Merck Chemicals Limited, Nottingam, UK) to 1/1000;
anti-phospho mTOR (ser2448) to 1/500, anti-mTOR (L27D4) to
1/5000 both from Cell Signaling Technology (Ozyme, Saint-
Quentin-en-Yvelines, France); anti-phospho P70S6 kinase at
thr389 to 1/1000 and anti-P70S6 kinase to 1/1000, both from Cell
Signaling Technology; anti-phospho AMPK at thr172 to 1/1000 and
anti-AMPK to 1/1000, both from Cell Signaling Technology, anti-
actin (MAB 1501R, Millipore) to 1/5000.
Secondary antibodies for immunohistochemistry were from
Jackson Immunoresearch West Grove. Anti-rabbit secondary anti-
body Alexa Fluor 488 or cy3 was diluted respectively to 1/200 and
to 1/500. Anti-mouse biotinylated antibody was diluted to 1/50 and
streptavidin cy3 to 1/200. Secondary goat anti-mouse horseradish
peroxidase (Biorad, Marnes-la-Coquette, France) diluted to 1/5000
and donkey anti-rabbit horseradish peroxidase (GE Healthcare,
Vélizy-Villacoublay, France) diluted to 1/1000 were used for
immunoblots.presented by the ratio to actin. For P-tau at ser202/thr205, ser356, P-mTOR, P-P70S6K, and P
Ratios are expressed in AU in mean  standard error of the mean. The signiﬁcances (see resu
kinase;mTOR,mammalian target of rapamycin; P-tau, phosphorylated tau. (For interpretation
this article.)2.3. Immunohistochemistry
Six Ts65Dn male mice and 5 euploid littermates of 3 month old
were analyzed for immunohistochemistry. To this end, mice were
deeply anesthezied with pentobarbital and perfused through the
ascending aorta with 4% paraformaldehyde in phosphate-buffered
saline (PBS) 0.1 M.
Brains were removed and postﬁxed overnight in the same
solution and cryoprotected by incubation in a 30% sucrose solution
for 48 hours. Brains were then frozen by immersion in isopentane
and stored at 80 C until sections were cut. Floating sagittal brain
sections (40 mm) were cut on a freezing microtome, collected and
stored at 4 C in sodium azide 2.5% in 0.1 M (PBS) until analysis.
Immunohistochemistry for APPcc, SET, and phosphorylated tau
(P-tau) was performed as previously described. Brieﬂy, after
blocking for 1 hour at room temperature in PBS with 5% bovine
serum albumin and 0.1% Triton X100, the sections were incubated
for overnight at 4 C in primary antibodies diluted in the blocking
buffer. After 3 rinses of 10 minutes in PBS, sections were incubated
for 90 minutes at room temperature in the secondary antibodies
diluted in PBS. The sections were then rinsed 3 times in PBS and
labeled by 0.1 mM TO-PRO-3 (Life Technologies, Illkirch, France) for
15 minutes. The sections were mounted in Fluoromount (Clin-
isciences, Nanterre, France).
Immunoﬂuorescence was performed at the PICPEN platform
(INSERM, UMR 894) using a TCS SP5 confocal imaging system
equipped with DPSS 561 nm and HeNe 633 nm lasers (Leica
Microsystems, Mannheim, Germany). Digital images of 8 bit were
collected in a sequential mode using an x63 plan Apochromat oil
immersion objective, a numerical aperture of 1.4 and the pinhole
size “airy 1”. Sections of 0.5 mm were performed. For each experi-
ment of the Ts65Dn and their euploid littermate mice, laser
intensity and image settings were adjusted and kept constant.
Image ﬂuorescence quantiﬁcation of the different sections was
performed in Volocity software.
2.4. Tissue extraction
Four Ts65Dnmale mice and 4 euploid littermates of 3 month old
were analyzed for Western blotting. To this end, mice were sacri-
ﬁced, their brain extracted and hippocampi were dissected and
sonicated at 4 C in 4 volumes of 50mM Tris buffer (pH 7.4), 0.15M
NaCl (TBS), 1% Triton X100, protease inhibitor cocktail 1X (Com-
plete, Roche Diagnostics, Mannheim, Germany) phosphatase
inhibitors (2mM Na3VO4 and 100mM NaF). Proteins were quanti-
ﬁed using micro BCA Protein assay kit (Thermo Scientiﬁc, Illkirsch,
France).
2.5. Western blotting
Standard SDS-PAGE on 10% Tris-HCl acrylamide gels and West-
ern blotting were performed. After electrophoresis, the proteins
were transferred onto polyvinylidene ﬂuoride membranes. After
saturation in TBS-Tween 0.2% with 5% low fat milk, the membranes
were incubated overnight at 4 C with primary antibodies. After 3
rinses with TBS-Tween 0.2%, membranes were incubated with
species-speciﬁc peroxidase-conjugated secondary antibodies for 1
hour at room temperature. The peroxidase signal was visualized by
enhanced chemiluminescence (ECL GE-Healthcare). Immunoblots-AMPK, the ratio of the phosphorylated form to their speciﬁc total native form is shown.
lts) are shown by asterisk (*). Abbreviations: AMPK, adenosine monophosphate protein
of the references to color in this ﬁgure legend, the reader is referred to theWebversion of
Fig. 2. Increase of APPcc in CA1 of Ts65Dn mice without changes in apoptotic nuclei.
(A) Fluorescence intensity of APPcc detected in CA1 by immunolabeling of brain slices
from the 6 Ts65Dn and 5 euploid littermates was analyzed by confocal microscopy and
quantiﬁed using Volocity software. Data are expressed in arbitray units (AU).
(B) Representative immunolabeling of APPcc in Ts65Dn and euploid littermate mice.
Nuclei are labeled with TOPRO-3 and presented in blue. Note the presence of APPcc in
terminals (arrowheads) in euploid littermates while it is highly detected in the
neuronal cytoplasm and neurites of Ts65Dn mice (arrow). Scale bar: 10 mm. (C) Per-
centage of apoptotic nuclei in CA1 from 5 Euploid and 6 Ts65Dn mice was evaluated in
sections labeled for SET, phosphorylated tau (P-tau) at ser202/thr205, and APPcc. The
nuclei were labeled by TOPRO-3. The apoptotic nuclei were counted in each ﬁeld of
70e90 cells. A total of about 1100 cells were counted for each genotype. Results are
presented as mean  standard error of the mean. No signiﬁcant difference was
observed between euploid and Ts65Dn mice (p ¼ 0.6017). Abbreviation: APPcc, amy-
loid precursor protein caspase cleaved. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the Web version of this article.)
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P70S6K, AMPK, Tau, immunoblots were ﬁrst performed for the
phosphorylated epitopes, and after stripping, the membranes were
incubated with the antibody to the respective total protein.
2.6. Statistical analysis
Analyses of the ﬂuorescence levels were performed using
ManneWhitney test. Correlation between 2 of the different
immunolabelings was evaluated by Spearman’s rho tests (Fredricks
and Nelsen, 2007).
3. Results
In CA1 of Ts65Dnmice, SETwas localized both in the nucleus and
in the neurites, whereas in euploid littermates, SET was exclusively
present in the nucleus (Fig. 1A,B,D). We observed a signiﬁcant in-
crease of SET immunolabeling both in the cell body including the
nucleus and in neurites in CA1 of the Ts65Dn as compared with
euploid mice (Ts65Dn vs. euploid mice: p ¼ 0.004; Fig. 1A). The
increase of SET immunolabeling was also signiﬁcant in the neurites
(Ts65Dn vs. euploid mice: p ¼ 0.004; Fig. 1B). In addition, P-tau at
ser202/thr205 was immunodetected by the AT8 antibody at low
levels in the euploid mice and at signiﬁcantly higher levels in
Ts65Dnmice (Ts65Dn vs. euploidmice: p¼ 0.004; Fig. 1C). The level
of SET translocated to the cytoplasm was signiﬁcantly correlated
with the total level of SET (Speerman rho ¼ 0.84; p ¼ 0.001).
SET and P-tau at ser202/thr205 levels in Ts65Dn and
euploid mice were signiﬁcantly correlated (Speerman rho ¼ 0.84;
p ¼ 0.001). Similar results were obtained when considering
the levels of SET and P-tau in neurites only (Speerman rho ¼ 0.87;
p ¼ 0.0001). Double immunohistochemistry showed that SET and
P-tau colocalized both in the cytoplasm and in the neurites (Fig.1D).
The increase in SET level, the translocation of SET in the cyto-
plasm and neurites, and the increase of P-tau in CA1 of Ts65Dn are
similar to what we observed in CA1 of DS patients (Facchinetti et al.,
2014).
The differences observed in SET and P-tau at ser202/thr205
levels between Ts65Dn and euploid mice were conﬁrmed
by immunoblotting (Fig. 1E; SET p ¼ 0.009; P-tau at ser202/thr205
p¼ 0.001). Signiﬁcant increase in P-tau levels were also observed at
ser356 in Ts65Dn mice (Fig. 1E; p ¼ 0.02).
We then examined the activation of mTOR complex 1 and of the
AMPK signaling pathways, already observedwhen PP2A is inhibited
(Magnaudeix et al., 2013). In Ts65Dn, a signiﬁcant increase in the
phosphorylation of mTOR at ser2448 (p ¼ 0.03) and of its substrate
P70S6K at thr389 (p ¼ 0.049) was observed (Fig. 1E), as in DS
patients (Iyer et al., 2014). We also observed in Ts65Dn an increase
in the phosphorylation of AMPK at thr172 as observed after PP2A
inhibition (p ¼ 0.049) (Magnaudeix et al., 2013). These activations
of mTORC1 and AMPK signaling pathways suggest that in addition
to tau hyperphosphorylation other cell events may be triggered
such as autophagy (Magnaudeix et al., 2013; Tramutola et al., 2016).
As we previously showed that overexpression of APPcc in CA1 of
wild-type mice is able to induce SET translocation not only in
cytoplasm but also in neurites, we examined the localization and
the level of APPcc in Ts65Dn and euploid mice. In euploid mice,
APPcc was present at neuron terminals whereas in Ts65Dn, APPcc
was highly present in the neuronal cytoplasm and in neurites
leading to a signiﬁcant increase of APPcc levels (Ts65Dn vs. euploid
mice: p ¼ 0.004; Fig. 2). The APPcc levels correlated with the
amount of SET (Speerman rho ¼ 0.77; p ¼ 0.005) and P-tau at
ser202/thr205 (Speerman rho ¼ 0.72; p ¼ 0.013).
Finally, we evaluated the putative apoptotic markers by quan-
tiﬁcation of the number and morphology of nuclei labeled by
E. Dorard et al. / Neurobiology of Aging 46 (2016) 43e48 47TOPRO-3. The percentage of dead cells was not signiﬁcantly
different between euploid and Ts65Dn mice (Fig. 2C).
4. Discussion
In this report, we show that SET is increased, translocated to the
cytoplasm of neurons from the CA1 of Ts65Dn mice leading to an
increase of tau phosphorylation at ser202/thr205 as observed in DS
and AD patients (Facchinetti et al., 2014). In addition, we also found
an increase in tau phosphorylation at ser356 and activation of
mTOR and AMPK signaling pathways, 2 other hallmarks of PP2A
inhibition.
Overexpressed Dyrk1A contributes to the neuroﬁbrillar degen-
eration in DS. In 60% of sporadic AD, Dyrk1A positive NFTs were
detected. However, a much higher percentage of Dyrk1A positive
NFTs was present in DS patients as compared with sporadic AD
cases (Ferrer et al., 2005; Wegiel et al., 2008). Dyrk1A predomi-
nantly phosphorylates tau at thr212 priming the GSK3-dependent
phosphorylation of tau at ser208 but also at several other sites
including ser202 and thr205 (Liu et al., 2008; Woods et al., 2001).
Increased tau phosphorylation at ser202/thr205 has been detected
before the formation of NFTs in AD brains (Braak et al., 1994) and is
present in dystrophic neurites and around amyloid cores in trans-
genic AD mouse models (Laporte et al., 2008; Nodo-Saita et al.,
2004; Otth et al., 2002). Tau phosphorylation at ser202 enhances its
polymerization, whereas phosphorylation at ser202 and thr205 not
only induces polymerization but also facilitates ﬁlament formation
(Rankin et al., 2005). Phosphorylation of tau at ser202/thr205 in the
brain of DS individuals may reﬂect AD pathology in DS. We previ-
ously showed in an ex vivo model that increase of SET in the
neuronal cytoplasm induced tau phosphorylation at ser202/thr205
and additional phosphorylations at other sites (Chasseigneaux
et al., 2014). We show here that tau at ser356 was also hyper-
phosphorylated, as already observed when PP2A is inhibited
(Bennecib et al., 2001; Magnaudeix et al., 2013), suggesting several
sites for tau hyperphosphorylation. In addition, we observed that
the overexpression of APPcc in the CA1 of wild-type mice is sufﬁ-
cient to induce the translocation of endogenous SET and thus the
increased phosphorylation of tau at ser202/thr205 (Facchinetti
et al., 2014). Consequently, SET translocated in the cytoplasm in-
creases tau phosphorylation at ser202/thr205 thus being involved
in the progression of the disease in AD but also in DS.
We observed here that SET and P-tau levels at ser202/thr205 are
signiﬁcantly correlated with APPcc levels. Increase of APPcc could
result from the overexpression of APP in Ts65Dn mice and
enhanced processing. Overexpression of wild-type APP induces
activation of caspase-3 in neurons both in vivo and in vitro leading
to the accumulation of APPcc (Nishimura et al., 1998, 2002).
Apoptosis has been observed in DS brain patients (Anderson et al.,
2000), but increase in Terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) positive cells or in caspase had not been
observed in 12-month-old Ts65Dn mice, contrary to a decrease
in Bcl-XL (Rueda et al., 2011). We did not observe any increase in
apoptotic nuclei in the CA1 of Ts65Dn mice unlike the increase in
APPcc. APP caspase cleavage is an event observed at early stages of
AD (Ayala-Grosso et al., 2002; Banwait et al., 2008; Zhao et al.,
2003). We used 3-month-old mice, whereas most of the studies
were performed on 12-month-old animals. In this sense, the loss of
cholinergic neurons in basal forebrain in Ts65Dn mice and its as-
sociation with cognitive decline start after 4 months (Granholm
et al., 2000). We previously observed in the brains of 3 DS pa-
tients that only 1 (48 years old) had an increase of APPcc suggesting
that in DS, other factors resulting from increased expression of
genes from chromosome 21 may be responsible for the increase of
SET, its translocation to the cytoplasm, and the increase of tauphosphorylation at ser202/thr205. Indeed, both
tau-phosphorylated sites recognized by the AT8 antibody were also
detected in the DS mouse model Ts1Cje in the absence of NFT
formation and of APP-triplicated gene (Shukkur et al., 2006).
Translocation of SET to the cytoplasm was found in 5 of the 6
Ts65Dn and correlated with SET levels: the higher the level of SET
the higher the translocation. The mouse without translocation of
SET had the lowest P-tau level at ser202/thr205 conﬁrming the
relationship between SET translocation and tau phosphorylation at
ser202/thr205. In hippocampus of DS patients, SET was largely
increased and associated to tau phosphorylation at ser202/thr205
(Facchinetti et al., 2014). The increased SET levels in Ts65Dn is not
due to a higher gene copy number like APP and Dyrk1A (Duchon
et al., 2011) because SET maps to Mouse chromosome 2 (Asaka
et al., 2008) and to Human chromosome 9 (von Lindern et al.,
1992). However, SET expression could be regulated by a gene or a
set of genes that are in 3 copies in DS. As the translocation of SET in
the neuronal cytoplasm of CA1 is associated with high levels of SET,
molecules able either to decrease the level of SET or decrease the
interaction of SET with PP2A would allow to slow down the
progression of the disease particularly the shift to AD pathology as
assessed by tau hyperphosphorylation. The activations of the mTOR
and AMPK signaling pathways in Ts65Dn as observed in conditions
of PP2A inhibition suggest that other deleterious mechanisms such
as inhibition of autophagy, which can induce the accumulation of
protein oxidative damage, may be the consequence of SET in the
cytoplasm inhibiting PP2A. Indeed, PP2A inhibition either by
okadaic acid or by knock down of PP2A catalytic subunit activates
these signaling pathways, which were associated to the autophagy
inhibition (Magnaudeix et al., 2013). Activation of mTOR was
already observed in DS patients (Iyer et al., 2014). More recently, it
has been reported an hyperphosphorylation of mTOR coupled with
the reduction of autophagosome formation in hippocampi of
Ts65Dn (Tramutola et al., 2016).
Taken together, we suggest that Ts65Dn mice could be a model
to test therapeutic approaches aiming at decreasing SET level and
its translocation to the cytoplasm leading to tau hyper-
phosphorylation and associated deleterious mechanisms, respon-
sible of the disease progression in DS.Disclosure statement
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